On October 5, American biopharmaceutical firm Amgen filed a supplemental brief at the U.S. Supreme Court, which comes about two weeks after the U.S. Solicitor General’s office filed a brief urging the Court to deny certiorari on Amgen’s petition for writ. Amgen’s petition seeks Supreme Court review of rulings in the lower courts invalidating Amgen’s patent claims for lack of enablement. Amgen’s latest brief argues that Solicitor General’s own arguments further support Supreme Court review to clarify the proper standard for reviewing questions of enablement under 35 U.S.C. § 112.
Recent Posts
- Only Congressional Patent Reform Can Restore Constitutional Rights
- ParkerVision is Latest to Petition SCOTUS for Review of CAFC’s ‘Heavy Reliance’ on Rule 36
- Other Barks & Bites for Friday, November 8: Judge Dismisses Copyright Lawsuit Against OpenAI Filed by News Outlets; Reports Finds Record Number of Global Patent Filings; ITC Finds Semiconductor Company Infringed on Competitor’s Patent
- How Bayh-Dole Supporters Made a Successful Goal Line Stand
- How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards